Consultant Medical Oncologist Germ Cell and Sarcoma

at  Nottingham University Hospitals NHS Trust

PENDING COLLEGE APPROVAL.

Due to relocation of the current post-holder, an exciting opportunity has arisen to appoint a new consultant in Medical Oncology with a responsibility for Sarcoma (including GISTs) and Germ Cell Tumours for Nottingham University Hospitals NHS Trust.
The post will be subject to the Terms and Conditions of the 2003 Consultant Contract. Candidates who prefer one of the advertised tumour sites with an alternative second tumour site are encouraged to discuss their preferences. The post will be based at Nottingham City Hospital Campus (alternative second tumour sites may require outpatient clinics at Kings Mill Hospital). The advertised role includes a small amount of CUP (cancer of unknown primary) work.
This is a full time post (10 PAs) but we are open to applications from people wishing to work less than full time or adopt a flexible full time working pattern. The job plan could be tailored to the successful candidate’s desired working pattern, experience and interests. There is the opportunity for an appropriately qualified / experienced candidate to take on the role of germ cell lead for the East Midlands or to include a third tumour site. Additional leadership roles are also available for experienced candidates. Candidates who prefer just one of the advertised tumour sites with an alternative second tumour site are encouraged to discuss their preferences.

PENDING COLLEGE APPROVAL.

Sarcoma
The sarcoma teams are multidisciplinary teams of plastic, orthopaedic and abdominal surgeons, medical and clinical oncologists and specialist trainees (in oncology usually one medical and one clinical oncology trainee), radiologists and pathologists, supported by Clinical Nurse Specialists (CNSs) and sarcoma physiotherapists, and access to dedicated onco-psychology services. NUH hosts the East Midlands main sarcoma MDT (the supra-regional MDT discusses approx. 250 new sarcoma diagnoses per annum) and currently supports sarcoma patients in the catchment area of Nottingham City and County as well as Lincolnshire. Patients in Derbyshire are treated at the Royal Derby Hospital, with the exception of patients undergoing curative treatment for bone sarcomas.
Germ Cell Tumours (GCT)
You will be joining a multidisciplinary team treating GCT at NUH. NUH hosts the East Midlands GCT MDT covering the five East Midlands cancer networks (Nottingham, Leicester, Derby, Lincoln and Northampton) as well as the Arden network (Coventry and Warwickshire). This MDT discusses 500-600 new cases a year. All patients with poor prognosis metastatic or relapsed GCT and patients with primary intracranial GCT are managed at NUH. Patients with stage 1, good and intermediate prognosis metastatic GCT are managed in their local centre, although patients with intermediate prognosis metastatic disease are offered participation in the accelerated BEP trial at NUH.
The speciality serves a resident population of 1.1 million and currently sees approximately 5,000 new patients each year (at City Hospital and Kings Mill Hospital in Mansfield); providing a comprehensive range of non-surgical oncology services to the Nottingham City and County and tertiary non-surgical oncology services to the East Midlands. Supra-regional networks, including the sarcoma and germ cell service, serve a resident population of over 4 million.
The Oncology Service has four dedicated oncology inpatient wards with 66 beds, which includes a dedicated Teenage and Young Adult Unit and its own oncology outpatient department. There are 2 outpatient systemic therapy wards with 35 chairs and beds as well as a clinic at KMH with a further 11 chairs.
The Oncology consultant team of 15 medical oncologists and 24 clinical oncologists provide site specialist care in multi-disciplinary teams. There is an established Medical Oncology Higher Specialist Training programme (9 posts), a highly successful Academic training programme (ACFs & ACLs) and a Clinical Oncology programme (13 posts). There are 11 F1-IMT3 trainees and 6 Oncology Clinical Fellows. We have an active Oncology Digital Technology Team, which is a national leader in developing ePROMS for patients on treatment with chemotherapy, immunotherapy and radiotherapy.
.
Please see detailed Job Description and Person Specification attached that details the role in more depth

Please refer the Job description for details